

2024

- 01/2024 Dermitzakis EV, Vikelis M, Xiromerisiou G; Rallis D; Soldatos P, Litsardopoulos P, Rikos D, Argyriou AA
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine.
J. Clin. Med. 2024, 13, 386.
(Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)
- 02/2024 Argyriou, AA; Dermitzakis, EV; Rikos, D; Xiromerisiou, G; Soldatos, P; Litsardopoulos, P; Vikelis, M.
Effects of Onabotulinumtoxin A on Allodynia and Interictal Burden of Patients with Chronic Migraine.
Toxins 2024, 16, 106
(Ηλεκτρονική διεύθυνση επικοινωνίας: andargyriou@yahoo.gr)
- 03/2024 Rikos D, Vikelis M, Dermitzakis EV, Soldatos P, Rallis D, Rudolf J, Andreou AP, Argyriou AA.
Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review.
J Clinical Medicine. 2024 Mar 28;13(7):1964
(Ηλεκτρονική διεύθυνση επικοινωνίας: rikosd@hotmail.com)
- 05/2024 Dermitzakis EV, Argyriou AA, Biliak K, Barmpa E, Liapi S, Rikos D, Xiromerisiou G, Soldatos P, Vikelis M.
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options.
J Clinical Medicine. 2024; 13(10): 2768
(Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)
- 05/2024 Gklinos P, Mitsikostas DD.
Headache disorders in multiple sclerosis: Is there an association? A systematic review and meta-analysis.
Mult Scler Relat Disord. 2024;85:105536.
(Ηλεκτρονική διεύθυνση επικοινωνίας: gklinosp@gmail.com)
- 06/2024 M. Vikelis, D. Rikos, AA. Argyriou, P. Papachristou, D. Rallis, T. Karapanayiotides, A. Galanopoulos, K. Spingos, N. Dimisianos, E. Giakoumakis, P. Zavrdis, K. Notas, GS. Vlachos, P. Soldatos, K. Biliak, G. Xiromerisiou, J. Rudolf, EV. Dermitzakis & AM. Rapoport. *Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints.* *Expert Rev Neurother.* 2024; 24(8), 815–26
(Ηλεκτρονική διεύθυνση επικοινωνίας: mvikelis@headaches.gr)
- 06/2024 Kodounis M., Constantinidis T.S., Rizonaki K., Drakou E., Zintzaras E., Stefanidis I., Mitsikostas D.D., Dardiotis E.

A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine.

Cureus. 2024 Jun 16;16(6):e62458.

(Ηλεκτρονική διεύθυνση επικοινωνίας: kodounis@gmail.com)

- 08/2024 Dermitzakis E., Argyriou A., Xiromerisiou G., Vikelis M.
OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine.
J OF HEADACHE AND PAIN (Vol. 25)
(Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)
- 08/2024 Papasavva M, Vikelis M, Siokas V, Katsarou MS, Dermitzakis E, Raptis A et al.
Investigation of the association between genetic variability in oxidative stress related factors and migraine.
J OF HEADACHE AND PAIN (Vol. 25)
(Ηλεκτρονική διεύθυνση επικοινωνίας: mariapapa@pharm.uoa.gr)
- 08/2024 Dermitzakis E., Vikelis M., & Argyriou A.
The significance of the circadian time of administration on the effectiveness and tolerability of OnabotulinumtoxinA for chronic migraine prophylaxis.
J OF HEADACHE AND PAIN (Vol. 25)
(Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)
- 08/2024 Sofia Liapi, Emmanouil V. Dermitzakis.
Subjective experience of migraine sufferers: psychoemotional experience and quality of life of sufferers.
Archives of Clinical Neurology 3:4-2024, 43-47
(Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)
- 09/2024 Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rikos D, Rallis D, Soldatos P, Litsardopoulos P, Andreou AP, Vikelis M.
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry.
Expert Rev Neurother. 2024; 24(11), 1119–26
(Ηλεκτρονική διεύθυνση επικοινωνίας: andargyriou@yahoo.gr)
- 11/2024 Dermitzakis EV; Rikos D; Vikelis M; Xiromerisiou G; Zisopoulou S; Rallis D; Soldatos P; Vlachos GS; Vasiliadis GG; Argyriou AA.
Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study.
Brain Sci. 2024; 14, 1169
(Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)